Latest Clinical Trials
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) National Heart, Lung, and Blood Institute (NHLBI) NA
RECRUITING
(Sep 18, 2026)
PHASE2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Taiho Oncology, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE1 Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART University of Aarhus NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML Ryvu Therapeutics SA NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE1 Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) AbbVie NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) AbbVie NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center NA
TERMINATED
(Aug 1, 2026)
PHASE1, PHASE2 Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma AbbVie NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL German CLL Study Group NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Venetoclax After TKI to Target Persisting Stem Cells in CML Thomas Ernst, PD Dr. med. NA
COMPLETED
(Aug 1, 2026)
PHASE2 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies AbbVie NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) BeOne Medicines NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Janssen Research & Development, LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1 Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies Nurix Therapeutics, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML M.D. Anderson Cancer Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Kerry Rogers NA
RECRUITING
(Aug 1, 2026)
PHASE2 Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia The First Affiliated Hospital of Xiamen University NA
RECRUITING
(Aug 1, 2026)
PHASE2 Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia Gruppo Italiano Malattie EMatologiche dell'Adulto NA
COMPLETED
(Jul 1, 2026)
PHASE2 Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma Chinese PLA General Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies Lomond Therapeutics Holdings, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE1 Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Medical College of Wisconsin NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors Treeline Biosciences, Inc. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study National Cancer Institute (NCI) NA
RECRUITING
(Jun 1, 2026)
PHASE3 Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
TERMINATED
(Jun 1, 2026)
PHASE2 Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Vanderbilt-Ingram Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients French Innovative Leukemia Organisation NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) Dizal Pharmaceuticals NA
RECRUITING
(Jun 1, 2026)
PHASE2 Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Jennifer Woyach NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial AbbVie NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Emory University NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia University of Michigan Rogel Cancer Center NA
TERMINATED
(May 1, 2026)
PHASE2 A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL Georgetown University NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial University of Utah NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
TERMINATED
(Apr 1, 2026)
PHASE2 Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study) Thomas Aagaard Rasmussen NA
RECRUITING
(Apr 1, 2026)
PHASE1 A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML MEI Pharma, Inc. NA
TERMINATED
(Mar 1, 2026)
PHASE1 Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) University of Illinois at Chicago NA
COMPLETED
(Mar 1, 2026)
PHASE1 Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL Gruppo Italiano Malattie EMatologiche dell'Adulto NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Gottfried von Keudell, MD PhD NA
RECRUITING
(Mar 1, 2026)
PHASE2 A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML Servier Bio-Innovation LLC NA
TERMINATED
(Mar 1, 2026)
PHASE1, PHASE2 A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) BeOne Medicines NA
RECRUITING
(Mar 1, 2026)
PHASE3 Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) PETHEMA Foundation NA
RECRUITING
(Mar 1, 2026)
PHASE3